Citigroup Initiates Coverage On Maze Therapeutics with Buy Rating, Announces Price Target of $50
Citigroup analyst Eric Joseph initiates coverage on Maze Therapeutics (NASDAQ:MAZE) with a Buy rating and announces Price Target of $50.
Stocks · News reference
HC Wainwright & Co. Reiterates Buy on Maze Therapeutics, Maintains $110 Price Target
HC Wainwright & Co. analyst Ananda Ghosh reiterates Maze Therapeutics (NASDAQ:MAZE) with a Buy and maintains $110 price target.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday
U.S. stocks fell as Nasdaq dropped 100+ points, while TriSalus surged 5.8% on FDA clearance; Securitize, Lakefront and others also gained.
Wedbush Reiterates Outperform on Maze Therapeutics, Maintains $48 Price Target
Wedbush analyst Laura Chico reiterates Maze Therapeutics (NASDAQ:MAZE) with a Outperform and maintains $48 price target.